Dr Aley joined the Oxford Vaccine Group in May 2016 and later played a pivotal role in the clinical trial operations for the Oxford-AstraZeneca COVID-19 vaccine, supporting not only the delivery of the trials in UK, Brazil and South Africa, but working with partners to ensure market authorisation of the vaccine at a global scale. She is responsible for the strategic oversight and direction of activity for the Oxford Vaccine Group, with the aim to facilitate research on the development and implementation of vaccines.